Introduction: To thoroughly examine the psycho-social impact of contralateral prophylactic mastectomy (CPM) among Hong Kong Chinese females with contralateral breast cancer history who underwent BRCA1/2 genetic testing. This aims to be first study of its kind in Chinese patients. Material and Methods: 11 female BRCA1/BRCA 2 mutated gene carriers and 1 non-carrier with history of contralateral breast cancer and genetic testing performed by the Hong Kong Hereditary Breast Cancer Family Registry subsequently underwent CPM. They were surveyed by a face-to-face or telephone interview. Breast cancer history, types of prophylactic mastectomy and reconstruction, overall and cosmetic satisfaction, pain, body image and sexuality issues, cancer ris...
Contralateral prophylactic mastectomy (CPM) is one option for reducing the risk of a second breast c...
PURPOSE: To assess intention to undergo prophylactic bilateral mastectomy and psychologic determinan...
Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast and ovarian cancer. O...
Research CommunicationOBJECTIVE: This qualitative study retrospectively examined the experience and ...
Item does not contain fulltextGenetic testing enables women at risk for hereditary breast and/or ova...
OBJECTIVES: For women who have been diagnosed with unilateral breast cancer there is an increasing t...
Purpose: The aim of this study was to explore the influences on satisfaction with reconstructed brea...
Women who inherit the BRCA1/2 gene have up to an 85% lifetime chance of developing breast cancer and...
© 2019 John Wiley & Sons, Ltd. Objective: Increasing numbers of women in the United Kingdom are ch...
© 2017 Elsevier B.V. Objective: The objective of this study was to explore the influences on decisio...
Abstract Objective The rate of contralateral prophylactic mastectomy (CPM) in women with early, unil...
Objective: Conduct a systematic review of quantitative and qualitative studies exploring patient rep...
Katharine Yao,1 Mark Sisco,2 Isabelle Bedrosian3 1Division of Surgical Oncology, Department of Surg...
Background: Prophylactic mastectomies in carriers of mutations in BRCA1 or BRCA2 are becoming increa...
Background: A breast cancer type 1 and type 2 susceptibility protein (BRCA1/BRCA2) gene mutation car...
Contralateral prophylactic mastectomy (CPM) is one option for reducing the risk of a second breast c...
PURPOSE: To assess intention to undergo prophylactic bilateral mastectomy and psychologic determinan...
Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast and ovarian cancer. O...
Research CommunicationOBJECTIVE: This qualitative study retrospectively examined the experience and ...
Item does not contain fulltextGenetic testing enables women at risk for hereditary breast and/or ova...
OBJECTIVES: For women who have been diagnosed with unilateral breast cancer there is an increasing t...
Purpose: The aim of this study was to explore the influences on satisfaction with reconstructed brea...
Women who inherit the BRCA1/2 gene have up to an 85% lifetime chance of developing breast cancer and...
© 2019 John Wiley & Sons, Ltd. Objective: Increasing numbers of women in the United Kingdom are ch...
© 2017 Elsevier B.V. Objective: The objective of this study was to explore the influences on decisio...
Abstract Objective The rate of contralateral prophylactic mastectomy (CPM) in women with early, unil...
Objective: Conduct a systematic review of quantitative and qualitative studies exploring patient rep...
Katharine Yao,1 Mark Sisco,2 Isabelle Bedrosian3 1Division of Surgical Oncology, Department of Surg...
Background: Prophylactic mastectomies in carriers of mutations in BRCA1 or BRCA2 are becoming increa...
Background: A breast cancer type 1 and type 2 susceptibility protein (BRCA1/BRCA2) gene mutation car...
Contralateral prophylactic mastectomy (CPM) is one option for reducing the risk of a second breast c...
PURPOSE: To assess intention to undergo prophylactic bilateral mastectomy and psychologic determinan...
Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast and ovarian cancer. O...